Difference between revisions of "Imatinib (Gleevec)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
Line 1: Line 1:
 
Also known as imatinib mesylate.
 
Also known as imatinib mesylate.
 
==General information==
 
==General information==
Class/mechanism: <ref name="insert">[http://www.pharma.us.novartis.com/product/pi/pdf/gleevec_tabs.pdf Imatinib (Gleevec) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/imatinib.pdf Imatinib (Gleevec) package insert (locally hosted backup)]</ref>
+
Class/mechanism: Tyrosine kinase inhibitor, inhibits multiple tyrosine kinases, including Bcr-Abl tyrosine kinase, the constitutively active tyrosine kinase resulting from the Philadelphia chromosome abnormality in CML; the receptor tyrosine kinases for platelet-derived growth factor (PDGF), stem cell factor (SCF), and c-kit, which is the activating mutation found in gastrointestinal stromal tumor (GIST) tumors.<ref name="insert">[http://www.pharma.us.novartis.com/product/pi/pdf/gleevec_tabs.pdf Imatinib (Gleevec) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/imatinib.pdf Imatinib (Gleevec) package insert (locally hosted backup)]</ref>
<br>Route: TBD
+
<br>Route: PO
<br>Extravasation: TBD
+
<br>Extravasation: n/a
  
 
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer.  Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>.  
 
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer.  Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>.  
Line 9: Line 9:
 
==Patient drug information==
 
==Patient drug information==
 
*[http://chemocare.com/bio/imatinib_mesylate.asp Imatinib (Gleevec) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/imatinib_mesylate.asp Imatinib (Gleevec) patient drug information (Chemocare)]</ref>
 
*[http://chemocare.com/bio/imatinib_mesylate.asp Imatinib (Gleevec) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/imatinib_mesylate.asp Imatinib (Gleevec) patient drug information (Chemocare)]</ref>
*[http://www.uptodate.com/contents/imatinib-patient-drug-information Imatinib (Gleevec) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/imatinib-patient-drug-information Imatinib (Gleevec) patient drug information (UpToDate)]</ref>
+
*[http://www.uptodate.com/contents/imatinib-gleevec-patient-drug-information Imatinib (Gleevec) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/imatinib-gleevec-patient-drug-information Imatinib (Gleevec) patient drug information (UpToDate)]</ref>
  
 
==References==
 
==References==
 
<references/>
 
<references/>

Revision as of 22:28, 10 February 2012

Also known as imatinib mesylate.

General information

Class/mechanism: Tyrosine kinase inhibitor, inhibits multiple tyrosine kinases, including Bcr-Abl tyrosine kinase, the constitutively active tyrosine kinase resulting from the Philadelphia chromosome abnormality in CML; the receptor tyrosine kinases for platelet-derived growth factor (PDGF), stem cell factor (SCF), and c-kit, which is the activating mutation found in gastrointestinal stromal tumor (GIST) tumors.[1][2]
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].

Patient drug information

References